Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL10934484 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL10931827 | 0.93 | TP53 (0.44) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL186171 | 0.92 | — | — | |
| L-Lactic Acid SCHEMBL22341771 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL19180003 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL668885 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL6709684 | 0.92 | — | — | |
| L-Lactic Acid SCHEMBL21815670 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL116857 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL671984 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119112174-A | Sensing detection and drug delivery integrated platform, needle tube array and method | 中山大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-118929793-A | Method for circularly producing tetrammine platinum salt | 云南贵金属实验室有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-115032297-A | Separation and detection method of trans-1, 2-diaminomethylcyclobutane and cis-isomer thereof | 四川汇宇制药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114835570-A | Synthesis method of trans-1, 2-diaminomethyl-cyclobutane and salt thereof | 上海寻科生物医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113416150-B | Synthetic method of lobaplatin intermediate | 上海寻科生物医药科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220047050-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC | 2022-02-17 | — | — | US | disclosed |
| WO-2022036259-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-9480260-B2 | Acrylic polymers containing metallic nanoparticles | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20040191329-A1 | Compositions and methods of metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-30 | — | — | US | disclosed |
| US-20040176312-A1 | Treatment of ungual and subungual diseases | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-09 | — | — | US | disclosed |
| US-20040131698-A1 | Methods of treating conditions using metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040129112-A1 | Metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040110738-A1 | Prophylactic treatment methods | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-06-10 | — | — | US | disclosed |
| WO-2004037187-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037186-A2 | PROPHYLACTIC TREATMENT METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
| US-20030095230-A1 | Antimicrobial lenses and methods of their use related patent applications | Ido, Koji (JP) | 2003-05-22 | — | — | US | disclosed |
| US-4505928-A | ANTITUMOR | ENGELHARD CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| US-4271085-A | ANTITUMOR AGENTS | ENGELHARD MINERALS & CHEMICALS CORPORATION (US) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | TP53 853/4885CA1 3748/4885CA4 4079/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | TP53 673/4885CA1 4100/4885CA4 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.